Literature DB >> 14709757

Effects of duloxetine on painful physical symptoms associated with depression.

David J Goldstein1, Yili Lu, Michael J Detke, James Hudson, Smriti Iyengar, Mark A Demitrack.   

Abstract

Painful physical symptoms are common features of major depressive disorder and may be the presenting complaints in primary care settings. The effect of the dual serotonin (5-HT) and norepinephrine reuptake inhibitor duloxetine on emotional and painful physical symptoms in outpatients with major depressive disorder was evaluated in three randomized, double-blind, placebo-controlled trials. The trials' primary objective was to evaluate the effect of duloxetine on mood, and subjects were not enrolled on the basis of presence, type, or severity of pain. However, the pain-relieving effects of duloxetine were evaluated by a priori defined analyses of results from a visual analogue scale and the Somatic Symptom Inventory. Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709757     DOI: 10.1176/appi.psy.45.1.17

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  34 in total

1.  Duloxetine for pain symptoms in patients with major depressive disorder.

Authors:  Prakash S Masand; Rajnish Mago
Journal:  Curr Psychiatry Rep       Date:  2005-06       Impact factor: 5.285

2.  Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Authors:  Syed I M Thiwan; Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-09

3.  Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials.

Authors:  Susan G Ball; Durisala Desaiah; Melissa E Spann; Qi Zhang; James M Russell; Michael J Robinson; Koen Demyttenaere
Journal:  Prim Care Companion CNS Disord       Date:  2011

4.  Depression and pain: implications for symptomatic presentation and pharmacological treatments.

Authors:  Beverly Kleiber; Shailesh Jain; Madhukar H Trivedi
Journal:  Psychiatry (Edgmont)       Date:  2005-05

Review 5.  Newer agents for the treatment of painful diabetic peripheral neuropathy.

Authors:  Roy Freeman
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

6.  Association between Painful Physical Symptoms and Clinical Outcomes in Korean Patients with Major Depressive Disorder: A Three-Month Observational Study.

Authors:  Min Soo Lee; Sun Young Yum; Jin Pyo Hong; Se Chang Yoon; Jai Sung Noh; Kwang Hun Lee; Jung Ki Kim; Sang Yeol Lee; Pritibha Singh; Tamas Treuer; Victoria Reed; Joel Raskin
Journal:  Psychiatry Investig       Date:  2009-12-08       Impact factor: 2.505

7.  A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.

Authors:  Amy S Chappell; Laurence A Bradley; Curtis Wiltse; Michael J Detke; Deborah N D'Souza; Michael Spaeth
Journal:  Int J Gen Med       Date:  2008-11-30

8.  Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients.

Authors:  Matthew J Bair; Jingwei Wu; Teresa M Damush; Jason M Sutherland; Kurt Kroenke
Journal:  Psychosom Med       Date:  2008-09-16       Impact factor: 4.312

9.  Implications of pain in generalized anxiety disorder: efficacy of duloxetine.

Authors:  James T Hartford; Jean Endicott; Susan G Kornstein; Christer Allgulander; Madelaine M Wohlreich; James M Russell; David G S Perahia; Janelle S Erickson
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

10.  Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders.

Authors:  Madhusudan Grover; Spencer D Dorn; Stephan R Weinland; Christine B Dalton; Bradley N Gaynes; Douglas A Drossman
Journal:  Dig Dis Sci       Date:  2009-02-26       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.